Gynecologie Obstetrique & Fertilite最新文献

Modern surgery tends to the improvement of minimally invasive strategies. Laparoscopy, rooted in practices for years, supplanted laparotomy in many directions. Regarding the extraction of large uterus, morcellation is currently the only way to externalize surgical specimens (myomas, uterine), without increasing the skin opening while allowing to reduce postoperative complications compared to laparotomy. However, in 2014, the Food and Drug Administration (FDA) discourages the use of uterine morcellation because of oncological risk. This recommendation has been challenged by a part of the profession. Our review has sought to identify the evidence for and against the use of morcellation. We also tried to quantify surgical risk and the current means of prevention. The incidence of uterine sarcomas is still poorly identified and preoperative diagnostic facilities remain inadequate. The small number of retrospective studies currently available could not enable any recommendation. The evaluation of morcellation devices and the improvement of preoperative diagnosis modalities (imaging, preoperative biopsy) are to continue to minimize the oncological risk.

Objectives

Although the benefit of magnesium sulfate to prevent cerebral palsy in antenatal on very preterm infants has been shown, there is still reluctance to use it. The aim of this study was to conduct an assessment of our practice using magnesium sulfate to prevent cerebral palsy at Rouen University Hospital to report its feasibility and safety in order to spread its use.

Methods

Unicentric and retrospective study, at the University Hospital of Rouen, between January and June 2014. All patients who delivered before 33 weeks or considered at risk of imminent delivery before 33 weeks were included (n = 86).

Results

Among the patients who delivered before 33 weeks (n = 82), a magnesium sulfate loading dose was administrated in 91.5% of cases. Treatment was mainly established and monitored by midwives (98.6%), usually in the delivery room (82.4%), and with an average duration of administration of 8.9 ± 17.5 hours. The treatment had to be stopped in a patient who presented bradypnea associated with impaired consciousness.

Conclusion

Our study shows that magnesium sulfate can easily be prescribed in clinical practice.

Objectives

The aim of this study was to assess long-term pelvic floor symptoms after an obstetric anal sphincter injury (OASI).

Methods

This retrospective cohort study included 237 cases of OASI (0.86% of deliveries) identified at Poitiers University Hospital between 2000 and 2011. Symptoms were assessed using validated self-administered questionnaires, including Female Pelvic Floor Questionnaire, Pescatori anal incontinence score, EuroQoL five-dimension score, and pain visual analogue scale (VAS).

Results

One hundred and sixty women (67%) filled out the questionnaires, on average 46 months after delivery (8–152). Among them, 93 (54%) reported at least one symptom occurring “frequently” (the most common being dyspareunia), and 45 (28%) a symptom occurring “daily” (the most common being flatus incontinence). Anal incontinence was reported by 32 (20%) women, flatus incontinence “frequently” or “daily” by 28 (18%), and stool incontinence “frequently” or “daily” by 9 (6%). Urinary incontinence was reported “frequently” or “daily” by 27 women (17%) at stress, 17 (11%) at urge, and 11 (7%) at mixed circumstances. Prolapse symptoms were reported “frequently” or “daily” by 6 women (4%). Pain during intercourse was reported “frequently” or “daily” by 17 women (11%). Twenty-four women (18%) reported chronic pelvic pain (VAS score ≥ 4/10). Ninety-five percent of women reported a normal quality of life for mobility, self-care, and usual activities; however, alterations in pain/discomfort (32%) and anxiety/depression (33%) domains were frequently reported.

Conclusion

Pelvic floor symptoms 4 years after OASI were highly prevalent.

Estrogen-progestagen menopausal hormonal therapy (MHT) is recognized as carcinogenic to humans. The article presents the associations between MHT and breast, ovary and endometrial cancer risks, in particular according to treatment modalities. If MHT must be prescribed, it is recommended to use the lowest dose for the shortest possible duration. Discussing with the patient the benefits but also the risks and making regular gynecological follow-up are strongly encouraged.

Objectives

Our aim was to evaluate the accuracy of estimated fetal weight (EFW) by ultrasound at due date and the factors that could affect it.

Methods

We performed a retrospective study of 233 patients in 2014. An ultrasound was performed at due date consultation around 41 weeks of amenorrhea by midwives sonographer. EFW was calculated using the Hadlock's formula with 3 parameters (biparietal diameter, abdominal circumference and femur length) and then adjusted including the growth from the due date consultation to the day of delivery (25 g/day) and finally compared to birth weight (BW).

Results

The mean absolute weight difference between EFW adjusted and BW was 256 g [0; 910]. The mean absolute percentage error was 7.2 % [0; 24.5] and the proportion of the EFW adjusted within 10 % of BW was 69.1 %. There was a strong correlation between EFW adjusted and BW (R = 0.79). Obesity in early pregnancy or childbirth, excessive weight gain, the presence of oligoanamnios and fetal macrosomia had no influence on the estimated fetal weight. Indeed, the mean absolute percentage error of child who were macrosome and those were not, was similars (7.9 % vs 7.1 %, P = 0.407).

Conclusions

EFW by ultrasound at due date is performant. However, the adjustment by the effect growth does not improve accuracy. Fetal macrosomia do not decrease the accuracy of ultrasound to estimate the fetal weight at term.

Objectives

Since the recent evidence of a tubal origin of most ovarian cancers, opportunistic salpingectomy could be discussed as a prophylactic strategy in the general population and with hereditary predisposition. We aimed to survey French gynecological surgeons about their current surgical practice of prophylactic salpingectomy.

Methods

An anonymous online survey was sent to French obstetrician-gynaecologists and gynecological surgeons. There were 13 questions about their current clinical practice and techniques of salpingectomy during a benign hysterectomy or as a tubal sterilization method, salpingectomy versus salpingo-oophorectomy in the population with genetic risk, salpingectomy in relationship with endometriosis and questions including histopathological considerations.

Results

Among the 569 respondents, opportunistic salpingectomy was always performed between 42.48% and 43.44% during laparoscopic, laparoscopic-assisted vaginal or laparotomic hysterectomy and only 12.26% in case of vaginal route. In the genetic population, salpingo-oophorectomy was mainly performed. Tubal sterilization was often practiced by the hysteroscopic route. More than 90% of respondents didn’t perform salpingectomy in case of endometriosis. There was not any specific tubal histopathological protocol in 71.54% of cases.

Conclusions

Salpingectomy may be a preventing strategy in the low- and high-risk population. The survey's responses show that salpingectomy seems to be a current practice during benign hysterectomy for more than 40% doctors. However, there is not any change with no more salpingectomy in the population with genetic risk, or in case of endometriosis or tubal sterilization.